Plain-English translation of NCT03114462 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new radiation treatment called HYDRA (Stereotactic Hypofractionated Radioablation) for people with early-stage voice box cancer. HYDRA is a type of focused radiation therapy that delivers high doses of radiation very precisely to the tumor over just a few days. Researchers want to find the safest and most effective dose of this treatment.
Voice box cancer is usually treated with surgery or traditional radiation therapy, both of which can affect a person's ability to speak, swallow, and breathe normally. This trial is exploring whether HYDRA—a newer, more precise radiation approach—might offer an effective alternative that preserves voice quality and function.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive HYDRA radiation treatment 5 times over about 2 weeks. Each treatment session involves lying still for 30–45 minutes while wearing a head and neck mask to keep you perfectly positioned, followed by imaging scans and the actual radiation (which takes 5–10 minutes). You'll have speech and swallowing function checks at each treatment visit. After treatment ends, you'll return for follow-up visits at 6 weeks, 3 months, 6 months, and then periodically for up to 5 years to monitor how you're doing.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States